AcSé immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer types
Aurélien Marabelle(Institut Gustave Roussy), Christophe Massard(Institut Gustave Roussy), Khê Hoang‐Xuan(Sorbonne Université), Benoı̂t Rousseau(Memorial Sloan Kettering Cancer Center), Christophe Tournigand(Université Paris-Est Créteil), Martin Schlumberger(Unknown), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Bernard Escudier(Institut Gustave Roussy), Sylvie Chevret(Université Paris Cité), Laurent Mortier, Damien Pouessel(Institut Claudius Regaud), Alison Jaccard(Ludwig Cancer Research), Patricia Niccoli(Institut Paoli-Calmettes), Iris Pauporté(La Ligue Contre le Cancer), Isabelle Laure Ray-Coquard(Université Claude Bernard Lyon 1), Natalie Hoog-Labouret(Institut National du Cancer), François Janot(Centre Hospitalier Universitaire de Nantes), Daniel Couch(UniCancer Group)
Cited by 0
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k